1027542-31-9

Basic information

• Product Name: (S)-2-[(3S,7S)-3-((S)-2-Acetylsulfanyl-3-phenyl-propionylamino)-2-oxo-7-propyl-azepan-1-yl]-butyric acid methyl ester
• Synonyms: (S)-2-[(3S,7S)-3-((S)-2-Acetylsulfanyl-3-phenyl-propionylamino)-2-oxo-7-propyl-azepan-1-yl]-butyric acid methyl ester
• CAS NO: 1027542-31-9
• Molecular Weight: 476.637
• Mol File: 1027542-31-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-2-[(3S,7S)-3-((S)-2-Acetylsulfanyl-3-phenyl-propionylamino)-2-oxo-7-propyl-azepan-1-yl]-butyric acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-[(3S,7S)-3-((S)-2-Acetylsulfanyl-3-phenyl-propionylamino)-2-oxo-7-propyl-azepan-1-yl]-butyric acid methyl ester(1027542-31-9)
• EPA Substance Registry System: (S)-2-[(3S,7S)-3-((S)-2-Acetylsulfanyl-3-phenyl-propionylamino)-2-oxo-7-propyl-azepan-1-yl]-butyric acid methyl ester(1027542-31-9)

Safety Data

• Hazardous Substances Data: 1027542-31-9(Hazardous Substances Data)

Upstream product

• 76932-17-7 (S)-2-acetylthio-3-phenylpropanoic acid 
• 1027184-65-1 (S)-2-((3S,7S)-3-Amino-2-oxo-7-propyl-azepan-1-yl)-butyric acid methyl ester 
• 84688-11-9 (S)-2-(1,3-dioxoisoindolin-2-yl)-6-hydroxyhexanoic acid 
• 171900-74-6 (S)-2-[(S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-6-hydroxy-hexanoylamino]-butyric acid ethyl ester 
• 171900-75-7 <3S-(1R*,3α,7β)>-hexahydro-α-ethyl-2-oxo-3-phthalimido-7-(2-propenyl)-1H-azepine-1-acetic acid 
• 171900-66-6 <(3S)-(1R*,3α,7β)>-hexahydro-α-ethyl-2-oxo-3-phthalimido-7-propyl-1H-azepine-1-acetic acid methyl ester 
• 171900-71-3 <(S)-(R*,R*)>-α-<<2-(2,3-dihydro-1,3-dioxo-1H-isoindol-2-yl)-1,6-dioxohexyl>amino>butanoic acid ethyl ester 
• 171900-73-5 <3S-(1R*,3α,7β)>-hexahydro-α-ethyl-2-oxo-3-phthalimido-7-(2-propenyl)-1H-azepine-1-acetic acid methyl ester 
• 171900-72-4 <3S-(3α,6β,9aα)>-tetrahydro-3-ethyl-2,5-dioxo-6-phthalimidooxazolo<3,2-a>azepine-2,5(3H,6H)-dione 

Relevant articles and documents

Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.

A series of substituted monocyclic and bicyclic azepinones were incorporated as dipeptide surrogates in mercaptoacetyl dipeptides with the desire to generate a single compound which would potently inhibit both angiotensin-converting enzyme (ACE) and neutr